ONCOGENEX PHARMACEUTICALS, INC. (NASDAQ:OGXI) Files An 8-K Other Events

Item8.01

Attached hereto as Exhibit 99.1 is an investor presentation that
Achieve Life Science, Inc. (Achieve) plans to present during the
J.P.Morgan Healthcare Conference.

Reference is made to the Exhibit Index included with this Current
Report on Form 8-K.

Important Additional Information about the Proposed
Merger

This communication is being made in respect of the proposed
merger involving OncoGenex Pharmaceuticals, Inc. (OncoGenex) and
Achieve. OncoGenex intends to file a registration statement on
Form S-4 with the SEC, which will contain a joint proxy
statement/prospectus and other relevant materials, and plans to
file with the Securities and Exchange Commission (SEC) other
documents regarding the proposed transaction. The final joint
proxy statement/prospectus will be sent to the stockholders of
OncoGenex and Achieve. The joint proxy statement/prospectus will
contain information about OncoGenex, Achieve, the proposed merger
and related matters. Stockholders are urged to read
the joint proxy statement/prospectus (including any amendments or
supplements) and other documents filed with the SEC carefully in
their entirety when they become available, as they will contain
important information that stockholders should consider before
making a decision about the merger and related
matters.In addition to receiving the joint proxy
statement/prospectus and proxy card by mail, stockholders will
also be able to obtain the joint proxy statement/prospectus, as
well as other filings containing information about OncoGenex,
without charge, from the SECs website (http://www.sec.gov) or,
without charge, by directing a written request to:OncoGenex
Pharmaceuticals, Inc., 19820 North Creek Parkway,Suite 201,
Bothell, WA 98011, Attention: Investor Relations or to Achieve
Life Science, Inc., 30 Sunnyside Avenue, Mill Valley, CA 94941,
Attention: Rick Stewart.

This communication shall not constitute an offer to
sell or the solicitation of an offer to sell or the solicitation
of an offer to buy any securities, nor shall there be any sale of
securities in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction. No offering
of securities in connection with the proposed merger shall be
made except by means of a prospectus meeting the requirements of
Section10 of the Securities Act of 1933, as
amended.

Participants in Solicitation

OncoGenex and its executive officers and directors may be deemed
to be participants in the solicitation of proxies from OncoGenexs
stockholders with respect to the matters relating to the proposed
merger. Achieve and its officers and directors may also be deemed
a participant in such solicitation. Information regarding
OncoGenexs executive officers and directors is available in
OncoGenexs proxy statement on Schedule 14A, filed with the SEC on
April21, 2016. Information regarding any interest that OncoGenex,
Achieve or any of the executive officers or directors of
OncoGenex or Achieve may have in the transaction with Achieve
will be set forth in the joint proxy statement/prospectus that
OncoGenex intends to file with the SEC in connection with its
stockholder vote on matters relating to the proposed merger.
Stockholders will be able to obtain this information by reading
the joint proxy statement/prospectus when it becomes available.

2